Literature DB >> 31659433

Phenome-wide association study of TTR and RBP4 genes in 361,194 individuals reveals novel insights in the genetics of hereditary and wildtype transthyretin amyloidoses.

Antonella De Lillo1, Flavio De Angelis1, Marco Di Girolamo2, Marco Luigetti3, Sabrina Frusconi4, Dario Manfellotto2, Maria Fuciarelli1, Renato Polimanti5,6.   

Abstract

Transthyretin (TTR) gene has a causal role in a hereditary form of amyloidosis (ATTRm) and is potentially involved in the risk of wild-type transthyretin amyloidosis (ATTRwt). To understand the genetics of ATTRm and ATTRwt, we conducted a phenome-wide association study of TTR gene in 361,194 participants of European descent testing coding and non-coding variants. Among the 382 clinically relevant phenotypes tested, TTR non-coding variants were associated with 26 phenotypic traits after multiple testing correction. These included signs related to both ATTRm and ATTRwt such as chronic ischaemic heart disease (rs140226130, p = 2.00 × 10-6), heart failure (rs73956431, p = 2.74 × 10-6), atrial fibrillation (rs10163755, p = 4.63 × 10-6), dysphagia (rs2949506, p = 3.95 × 10-6), intestine diseases (rs970866, p = 7.14 × 10-6) and anxiety (rs554521234, p = 8.85 × 10-6). Consistent results were observed for TTR disease-causing mutation Val122Ile (rs76992529) with respect to carpal tunnel syndrome (p = 6.41 × 10-6) and mononeuropathies of upper limbs (p = 1.22 × 10-5). Sex differences were also observed in line with ATTRm and ATTRwt epidemiology. Additionally, we explored possible modifier genes related to TTR function, observing convergent associations of RBP4 variants with the clinical phenotypes associated with TTR locus. In conclusion, we provide novel insights regarding the molecular basis of ATTRm and ATTRwt based on large-scale cohort, expanding our understanding of the phenotypic spectrum associated with TTR gene variation.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31659433     DOI: 10.1007/s00439-019-02078-6

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  48 in total

1.  Gene ontology: tool for the unification of biology. The Gene Ontology Consortium.

Authors:  M Ashburner; C A Ball; J A Blake; D Botstein; H Butler; J M Cherry; A P Davis; K Dolinski; S S Dwight; J T Eppig; M A Harris; D P Hill; L Issel-Tarver; A Kasarskis; S Lewis; J C Matese; J E Richardson; M Ringwald; G M Rubin; G Sherlock
Journal:  Nat Genet       Date:  2000-05       Impact factor: 38.330

Review 2.  Transthyretin amyloidosis and the kidney.

Authors:  Luísa Lobato; Ana Rocha
Journal:  Clin J Am Soc Nephrol       Date:  2012-04-26       Impact factor: 8.237

3.  Functional variation of the transthyretin gene among human populations and its correlation with amyloidosis phenotypes.

Authors:  Renato Polimanti; Marco Di Girolamo; Dario Manfellotto; Maria Fuciarelli
Journal:  Amyloid       Date:  2013-10-10       Impact factor: 7.141

4.  Most recent common ancestor of TTR Val30Met mutation in Italian population and its potential role in genotype-phenotype correlation.

Authors:  Andrea Iorio; Flavio De Angelis; Marco Di Girolamo; Marco Luigetti; Luca Pradotto; Alessandro Mauro; Dario Manfellotto; Maria Fuciarelli; Renato Polimanti
Journal:  Amyloid       Date:  2014-12-16       Impact factor: 7.141

5.  Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population.

Authors:  Urban Hellman; Flora Alarcon; Hans-Erik Lundgren; Ole B Suhr; Catherine Bonaiti-Pellié; Violaine Planté-Bordeneuve
Journal:  Amyloid       Date:  2008-09       Impact factor: 7.141

6.  Psychosocial impact of presymptomatic genetic testing for transthyretin amyloidotic polyneuropathy.

Authors:  Anita Graceffa; Massimo Russo; Gian Luca Vita; Antonio Toscano; Roberto Dattola; Corrado Messina; Giuseppe Vita; Anna Mazzeo
Journal:  Neuromuscul Disord       Date:  2008-12-11       Impact factor: 4.296

7.  Life paths of patients with transthyretin-related familial amyloid polyneuropathy Val30Met: a descriptive study.

Authors:  Alice Lopes; Alexandra Sousa; Isabel Fonseca; Margarida Branco; Carla Rodrigues; Teresa Coelho; Jorge Sequeiros; Paula Freitas
Journal:  J Community Genet       Date:  2017-10-19

8.  Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data.

Authors:  Joshua C Denny; Lisa Bastarache; Marylyn D Ritchie; Robert J Carroll; Raquel Zink; Jonathan D Mosley; Julie R Field; Jill M Pulley; Andrea H Ramirez; Erica Bowton; Melissa A Basford; David S Carrell; Peggy L Peissig; Abel N Kho; Jennifer A Pacheco; Luke V Rasmussen; David R Crosslin; Paul K Crane; Jyotishman Pathak; Suzette J Bielinski; Sarah A Pendergrass; Hua Xu; Lucia A Hindorff; Rongling Li; Teri A Manolio; Christopher G Chute; Rex L Chisholm; Eric B Larson; Gail P Jarvik; Murray H Brilliant; Catherine A McCarty; Iftikhar J Kullo; Jonathan L Haines; Dana C Crawford; Daniel R Masys; Dan M Roden
Journal:  Nat Biotechnol       Date:  2013-12       Impact factor: 54.908

Review 9.  Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP.

Authors:  Yesim Parman; David Adams; Laura Obici; Lucía Galán; Velina Guergueltcheva; Ole B Suhr; Teresa Coelho
Journal:  Curr Opin Neurol       Date:  2016-02       Impact factor: 5.710

10.  The UK Biobank resource with deep phenotyping and genomic data.

Authors:  Clare Bycroft; Colin Freeman; Desislava Petkova; Gavin Band; Lloyd T Elliott; Kevin Sharp; Allan Motyer; Damjan Vukcevic; Olivier Delaneau; Jared O'Connell; Adrian Cortes; Samantha Welsh; Alan Young; Mark Effingham; Gil McVean; Stephen Leslie; Naomi Allen; Peter Donnelly; Jonathan Marchini
Journal:  Nature       Date:  2018-10-10       Impact factor: 49.962

View more
  4 in total

1.  The integration of genetically-regulated transcriptomics and electronic health records highlights a pattern of medical outcomes related to increased hepatic transthyretin expression.

Authors:  Gita A Pathak; Antonella De Lillo; Frank R Wendt; Flavio De Angelis; Dora Koller; Brenda Cabrera Mendoza; Daniel Jacoby; Edward J Miller; Joel N Buxbaum; Renato Polimanti
Journal:  Amyloid       Date:  2021-12-22       Impact factor: 6.571

2.  Epigenomic Profiles of African-American Transthyretin Val122Ile Carriers Reveals Putatively Dysregulated Amyloid Mechanisms.

Authors:  Gita A Pathak; Frank R Wendt; Antonella De Lillo; Yaira Z Nunez; Aranyak Goswami; Flavio De Angelis; Maria Fuciarelli; Henry R Kranzler; Joel Gelernter; Renato Polimanti
Journal:  Circ Genom Precis Med       Date:  2021-01-11

3.  Epigenetic profiling of Italian patients identified methylation sites associated with hereditary transthyretin amyloidosis.

Authors:  Antonella De Lillo; Gita A Pathak; Flavio De Angelis; Marco Di Girolamo; Marco Luigetti; Mario Sabatelli; Federico Perfetto; Sabrina Frusconi; Dario Manfellotto; Maria Fuciarelli; Renato Polimanti
Journal:  Clin Epigenetics       Date:  2020-11-17       Impact factor: 6.551

4.  Correlation between Changes in Serum RBP4, hs-CRP, and IL-27 Levels and Rosuvastatin in the Treatment of Coronary Heart Disease.

Authors:  Yali Wang; Changrui Zhou; Tianlian Yu; Feng Zhao
Journal:  J Healthc Eng       Date:  2021-12-15       Impact factor: 2.682

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.